The role of allogeneic stem cell transplantation in relapsed/refractory Hodgkin's Lymphoma patients

Advances in Hematology

Volumn 2011, Issue , 2011, Pages

  Zander, Axel Rolf ^a   Klyuchnikov, Evgeny ^a   Bacher, Ulrike ^a   Krger, Nicolaus ^a   Kazantsev, Ilya ^a,b   Zabelina, Tatjana ^a   Ayuk, Francis ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIMITOTIC AGENT; BRENTUXIMAB; DOXORUBICIN; FLUDARABINE; GEMCITABINE; LENALIDOMIDE; MELPHALAN; MONOCLONAL ANTIBODY; MONOMETHYL AURISTATIN E; NAVELBINE; PENTOSTATIN; THALIDOMIDE; UNCLASSIFIED DRUG; VORINOSTAT;

ADOLESCENT HEALTH; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER RELAPSE; DONOR; GRAFT VERSUS LYMPHOMA EFFECT; HODGKIN DISEASE; HUMAN; LYMPHOCYTE DEPLETION; MYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

EID: 78650757451     PISSN: 16879104     EISSN: 16879112     Source Type: Journal    
DOI: 10.1155/2011/974658     Document Type: Review

References (83)

1. Connors J. M., State-of-the-art therapeutics: Hodgkin's lymphoma Journal of Clinical Oncology 2005 23 26 6400 6408
2. Linch D. C., Winfield D., Goldstone A. H., Moir D., Hancock B., McMillan A., Chopra R., Milligan D., Vaughan Hudson G., Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial The Lancet 1993 341 8852 1051 1054
3. Schmitz N., Pfistner B., Sextro M., Sieber M., Carella A. M., Haenel M., Boissevain F., Zschaber R., Mller P., Kirchner H., Lohri A., Decker S., Koch B., Hasenclever D., Goldstone A. H., Diehl V., Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial The Lancet 2002 359 9323 2065 2071
4. Domnguez A. R., Mrquez A., Gum J., Llanos M., Herrero J., de las Nieves M. A., Miramn J., Alba E., Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study Annals of Oncology 2004 15 12 1798 1804
5. Meyer R. M., Gospodarowicz M. K., Connors J. M., Pearcey R. G., Bezjak A., Wells W. A., Burns B. F., Winter J. N., Horning S. J., Dar A. R., Djurfeldt M. S., Ding K., Shepherd L. E., Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group Journal of Clinical Oncology 2005 23 21 4634 4642
6. Hasenclever D., Diehl V., A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease The New England Journal of Medicine 1998 339 21 1506 1514
7. Kewalramani T., Nimer S. D., Zelenetz A. D., Malhotra S., Qin J., Yahalom J., Moskowitz C. H., Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma Bone Marrow Transplantation 2003 32 7 673 679
8. Paltiel O., Rubinstein C., Or R., Nagler A., Gordon L., Deutsch L., Polliack A., Naparstek E., Factors associated with survival in patients with progressive disease following autologous transplant for lymphoma Bone Marrow Transplantation 2003 31 7 565 569
9. Lavoie J. C., Connors J. M., Phillips G. L., Reece D. E., Barnett M. J., Forrest D. L., Gascoyne R. D., Hogge D. E., Nantel S. H., Shepherd J. D., Smith C. A., Song K. W., Sutherland H. J., Toze C. L., Voss N. J. S., Nevill T. J., High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver Blood 2005 106 4 1473 1478
10. Moskowitz A. J., Perales M.-A., Kewalramani T., Yahalom J., Castro-Malaspina H., Zhang Z., Vanak J., Zelenetz A. D., Moskowitz C. H., Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma British Journal of Haematology 2009 146 2 158 163
11. Validire P., Ferm C., Brice P., Divin M., Gabarre J., Bouabdallah K., Fitoussi O., Chaoui D., Pacquement H., Soussain C., Carde P., Salhi R., Zanni M., Decaudin D., A multicenter study of gemcitabine-containing regimen in relapsed or refractory Hodgkin's lymphoma patients Anti-Cancer Drugs 2008 19 3 309 315
12. Lin T. S., Avalos B. R., Penza S. L., Marcucci G., Elder P. J., Copelan E. A., Second autologous stem cell transplant for multiply relapsed Hodgkin's disease Bone Marrow Transplantation 2002 29 9 763 767
13. Appelbaum F. R., Sullivan K. M., Thomas E. D., Allogeneic marrow transplantation in the treatment of MOPP-resistant Hodgkin's disease Journal of Clinical Oncology 1985 3 11 1490 1494
14. Phillips G. L., Reece D. E., Barnett M. J., Connors J. M., Fay J. W., Herzig G. P., Herzig R. H., Klingemann H.-G., Shepherd J. D., Wolff S. N., Allogeneic marrow transplantation for refractory Hodgkin's disease Journal of Clinical Oncology 1989 7 8 1039 1045
15. Jones R. J., Ambinder R. F., Piantadosi S., Santos G. W., Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation Blood 1991 77 3 649 653
16. Gajewski J. L., Phillips G. L., Sobocinski K. A., Armitage J. O., Gale R. P., Champlin R. E., Herzig R. H., Hurd D. D., Jagannath S., Klein J. P., Lazarus H. M., McCarthy P. L. Jr., Pavlovsky S., Petersen F. B., Rowlings P. A., Russell J. A., Silver S. M., Vose J. M., Wiernik P. H., Bortin M. M., Horowitz M. M., Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease Journal of Clinical Oncology 1996 14 2 572 578
17. Slavin S., Nagler A., Naparstek E., Kapelushnik Y., Aker M., Cividalli G., Varadi G., Kirschbaum M., Ackerstein A., Samuel S., Amar A., Brautbar C., Ben-Tal O., Eldor A., Or R., Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases Blood 1998 91 3 756 763
18. Khouri I. F., Keating M., Krbling M., Przepiorka D., Anderlini P., O'Brien S., Giralt S., Ippoliti C., Von Wolff B., Gajewski J., Donato M., Claxton D., Ueno N., Andersson B., Gee A., Champlin R., Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies Journal of Clinical Oncology 1998 16 8 2817 2824
19. Milpied N., Fielding A. K., Pearce R. M., Ernst P., Goldstone A. H., Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease Journal of Clinical Oncology 1996 14 4 1291 1296
20. Anderson J. E., Litzow M. R., Appelbaum F. R., Schoch G., Fisher L. D., Buckner C. D., Petersen F. B., Crawford S. W., Press O. W., Sanders J. E., Bensinger W. I., Martin P. J., Storb R., Sullivan K. M., Hansen J. A., Thomas E. D., Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience Journal of Clinical Oncology 1993 11 12 2342 2350
21. Akpek G., Ambinder R. F., Piantadosi S., Abrams R. A., Brodsky R. A., Vogelsang G. B., Zahurak M. L., Fuller D., Miller C. B., Noga S. J., Fuchs E., Flinn I. W., O'Donnell P., Seifter E. J., Mann R. B., Jones R. J., Long-term results of blood and marrow transplantation for Hodgkin's lymphoma Journal of Clinical Oncology 2001 19 23 4314 4321
22. Cooney J. P., Stiff P. J., Toor A. A., Parthasarathy M., BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective Biology of Blood and Marrow Transplantation 2003 9 3 177 182
23. Giralt S., Estey E., Albitar M., Van Besien K., Rondn G., Anderlini P., O'Brien S., Khouri I., Gajewski J., Mehra R., Claxton D., Andersson B., Beran M., Przepiorka D., Koller C., Kornblau S., Krbling M., Keating M., Kantarjian H., Champlin R., Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy Blood 1997 89 12 4531 4536
24. Storb R., Yu C., Wagner J. L., Deeg H. J., Nash R. A., Kiem H.-P., Leisenring W., Shulman H., Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation Blood 1997 89 8 3048 3054
25. Robinson S. P., Sureda A., Canals C., Russell N., Caballero D., Bacigalupo A., Iriondo A., Cook G., Pettitt A., Socie G., Bonifazi F., Bosi A., Michallet M., Liakopoulou E., Maertens J., Passweg J., Clarke F., Martino R., Schmitz N., Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome Haematologica 2009 94 2 230 238
26. Anderlini P., Saliba R., Acholonu S., Okoroji G.-J., Donato M., Giralt S., Andersson B., Ueno N. T., Khouri I., De Lima M., Hosing C., Cohen A., Ippoliti C., Romaguera J., Rodriguez M. A., Pro B., Fayad L., Goy A., Younes A., Champlin R. E., Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen Bone Marrow Transplantation 2005 35 10 943 951
27. Anderlini P., Saliba R., Acholonu S., Giralt S. A., Andersson B., Ueno N. T., Hosing C., Khouri I. F., Couriel D., De Lima M., Qazilbash M. H., Pro B., Romaguera J., Fayad L., Hagemeister F., Younes A., Munsell M. F., Champlin R. E., Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience Haematologica 2008 93 2 257 264
28. Sarina B., Castagna L., Farina L., Patriarca F., Benedetti F., Carella A. M., Falda M., Guidi S., Ciceri F., Bonini A., Ferrari S., Malagola M., Morello E., Milone G., Bruno B., Mordini N., Viviani S., Levis A., Giordano L., Santoro A., Corradini P., Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability Blood 2010 115 18 3671 3677
29. Devetten M. P., Hari P. N., Carreras J., Logan B. R., van Besien K., Bredeson C. N., Freytes C. O., Gale R. P., Gibson J., Giralt S. A., Goldstein S. C., Gupta V., Marks D. I., Maziarz R. T., Vose J. M., Lazarus H. M., Anderlini P., Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma Biology of Blood and Marrow Transplantation 2009 15 1 109 117
30. Burroughs L. M., O'Donnell P. V., Sandmaier B. M., Storer B. E., Luznik L., Symons H. J., Jones R. J., Ambinder R. F., Maris M. B., Blume K. G., Niederwieser D. W., Bruno B., Maziarz R. T., Pulsipher M. A., Petersen F. B., Storb R., Fuchs E. J., Maloney D. G., Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma Biology of Blood and Marrow Transplantation 2008 14 11 1279 1287
31. Claviez A., Canals C., Dierickx D., Stein J., Badell I., Pession A., Mackinnon S., Slavin S., Dalle J.-H., Chacn M. J., Sarhan M., Wynn R. F., Suttorp M., Dini G., Sureda A., Schmitz N., Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation Blood 2009 114 10 2060 2067
32. Alvarez I., Sureda A., Caballero M. D., Urbano-Ispizua A., Ribera J. M., Canales M., Garca-Conde J., Sanz G., Arranz R., Bernal M. T., de la Serna J., Dez J. L., Moraleda J. M., Rubi-Flix D., Xicoy B., Martnez C., Mateos M. V., Sierra J., Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: results of a Spanish prospective cooperative protocol Biology of Blood and Marrow Transplantation 2006 12 2 172 183
33. Peggs K. S., Sureda A., Qian W., Caballero D., Hunter A., Urbano-Ispizua A., Cavet J., Ribera J. M., Parker A., Canales M., Mahendra P., Garcia-Conde J., Milligan D., Sanz G., Thomson K., Arranz R., Goldstone A. H., Alvarez I., Linch D. C., Sierra J., MacKinnon S., Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes British Journal of Haematology 2007 139 1 70 80
34. Sureda A., Robinson S., Canals C., Carella A. M., Boogaerts M. A., Caballero D., Hunter A. E., Kanz L., Slavin S., Cornelissen J. J., Gramatzki M., Niederwieser D., Russell N. H., Schmitz N., Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the lymphoma working party of the European Group for Blood and Marrow Transplantation Journal of Clinical Oncology 2008 26 3 455 462
35. Kolb H.-J., Schattenberg A., Goldman J. M., Hertenstein B., Jacobsen N., Arcese W., Ljungman P., Ferrant A., Verdonck L., Niederwieser D., Van Rhee F., Mittermueller J., De Witte T., Holler E., Ansari H., Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients Blood 1995 86 5 2041 2050
36. Porter D. L., Roth M. S., McGarigle C., Ferrara J. L. M., Antin J. H., Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia The New England Journal of Medicine 1994 330 2 100 106
37. Tricot G., Vesole D. H., Jagannath S., Hilton J., Munshi N., Barlogie B., Graft-versus-myeloma effect: proof of principle Blood 1996 87 3 1196 1198
38. Grigg A., Ritchie D., Graft-versus-lymphoma effects: clinical review, policy proposals, and immunobiology Biology of Blood and Marrow Transplantation 2004 10 9 579 590
39. Maris M. B., Sandmaier B. M., Storer B. E., Chauncey T., Stuart M. J., Maziarz R. T., Agura E., Langston A. A., Pulsipher M., Storb R., Maloney D. G., Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma Blood 2004 104 12 3535 3542
40. Claviez A., Klingebiel T., Beyer J., Nrnberger W., Ehninger G., Suttorp M., Dreger P., Drffel W., Schmitz N., Allogeneic peripheral blood stem cell transplantation following fludarabine-based conditioning in six children with advanced Hodgkin's disease Annals of Hematology 2004 83 4 237 241
41. Peggs K. S., Hunter A., Chopra R., Parker A., Mahendra P., Milligan D., Craddock C., Pettengell R., Dogan A., Thomson K. J., Morris E. C., Hale G., Waldmann H., Goldstone A. H., Linch D. C., MacKinnon S., Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation The Lancet 2005 365 9475 1934 1941
42. Chemnitz J. M., Driesen J., Classen S., Riley J. L., Debey S., Beyer M., Popov A., Zander T., Schultze J. L., Prostaglandin E2 impairs CD4+ T cell activation by inhibition of lck: implications in Hodgkin's lymphoma Cancer Research 2006 66 2 1114 1122
43. Chemnitz J. M., Eggle D., Driesen J., Classen S., Riley J. L., Debey-Pascher S., Beyer M., Popov A., Zander T., Schultze J. L., RNA fingerprints provide direct evidence for the inhibitory role of TGF and PD-1 on CD4+ T cells in Hodgkin lymphoma Blood 2007 110 9 3226 3233
44. Kppers R., The biology of Hodgkin's lymphoma Nature Reviews Cancer 2009 9 1 15 27
45. Poppema S., Potters M., Visser L., Van Den Berg A. M., Immune escape mechanisms in Hodgkin's disease Annals of Oncology 1998 9 supplement 5 S21 S24
46. Skinnider B. F., Mak T. W., The role of cytokines in classical Hodgkin lymphoma Blood 2002 99 12 4283 4297
47. Diepstra A., Poppema S., Boot M., Visser L., Nolte I. M., Niens M., Te Meerman G. J., Van Den Berg A., HLA-G protein expression as a potential immune escape mechanism in classical Hodgkin's lymphoma Tissue Antigens 2008 71 3 219 226
48. Yamamoto R., Nishikori M., Kitawaki T., Sakai T., Hishizawa M., Tashima M., Kondo T., Ohmori K., Kurata M., Hayashi T., Uchiyama T., PD-1 PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma Blood 2008 111 6 3220 3224
49. Muenst S., Hoeller S., Dirnhofer S., Tzankov A., Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival Human Pathology 2009 40 12 1715 1722
50. Steidl C., Lee T., Shah S. P., Farinha P., Han G., Nayar T., Delaney A., Jones S. J., Iqbal J., Weisenburger D. D., Bast M. A., Rosenwald A., Muller-Hermelink H. -K., Rimsza L. M., Campo E., Delabie J., Braziel R. M., Cook J. R., Tubbs R. R., Jaffe E. S., Lenz G., Connors J. M., Staudt L. M., Chan W. C., Gascoyne R. D., Tumor-associated macrophages and survival in classic Hodgkin's lymphoma The New England Journal of Medicine 2010 362 10 875 885
51. Hirano F., Kaneko K., Tamura H., Dong H., Wang S., Ichikawa M., Rietz C., Flies D. B., Lau J. S., Zhu G., Tamada K., Chen L., Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity Cancer Research 2005 65 3 1089 1096
52. Carella A. M., Cavaliere M., Lerma E., Ferrara R., Tedeschi L., Romanelli A., Vinci M., Pinotti G., Lambelet P., Loni C., Verdiani S., De Stefano F., Valbonesi M., Corsetti M. T., Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hermatopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma Journal of Clinical Oncology 2000 18 23 3918 3924
53. Tzankov A., Meier C., Hirschmann P., Went P., Pileri S. A., Dirnhofer S., Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma Haematologica 2008 93 2 193 200
54. Barbon C. M., Yang M., Wands G. D., Ramesh R., Slusher B. S., Hedley M. L., Luby T. M., Consecutive low doses of cyclophosphamide preferentially target Tregs and potentiate T cell responses induced by DNA PLG microparticle immunization Cellular Immunology 2010 262 2 150 161
55. Greten T. F., Ormandy L. A., Fikuart A., Hchst B., Henschen S., Hrning M., Manns M. P., Korangy F., Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC Journal of Immunotherapy 2010 33 2 211 218
56. Majhail N. S., Weisdorf D. J., Wagner J. E., Defor T. E., Brunstein C. G., Burns L. J., Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma Blood 2006 107 9 3804 3807
57. Frankovich J., Donaldson S. S., Lee Y., Wong R. M., Amylon M., Verneris M. R., High-dose therapy and autologous hematopoietic cell transplantation in children with primary refractory and relapsed Hodgkin's disease: atopy predicts idiopathic diffuse lung injury syndromes Biology of Blood and Marrow Transplantation 2001 7 1 49 57
58. Lieskovsky Y. E., Donaldson S. S., Torres M. A., Wong R. M., Amylon M. D., Link M. P., Agarwal R., High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: results and prognostic indices Journal of Clinical Oncology 2004 22 22 4532 4540
59. Kennedy-Nasser A. A., Bollard C. M., Myers G. D., Leung K. S., Gottschalk S., Zhang Y., Liu H., Heslop H. E., Brenner M. K., Krance R. A., Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen Biology of Blood and Marrow Transplantation 2008 14 11 1245 1252
60. Malladi R. K., Peniket A. J., Littlewood T. J., Towlson K. E., Pearce R., Yin J., Cavenagh J. D., Craddock C., Orchard K. H., Olavarria E., McQuaker G., Collin M., Marks D. I., Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML Bone Marrow Transplantation 2009 43 9 709 715
61. Schreck S., Friebel D., Buettner M., Distel L., Grabenbauer G., Young L. S., Niedobitek G., Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma Hematological Oncology 2009 27 1 31 39
62. Besien K. V., Kunavakkam R., Rondon G., De Lima M., Artz A., Oran B., Giralt S., Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes Biology of Blood and Marrow Transplantation 2009 15 5 610 617
63. van Dorp S., Pietersma F., Wlfl M., Verdonck L. F., Petersen E. J., Lokhorst H. M., Martens E., Theobald M., van Baarle D., Meijer E., Kuball J., Rituximab treatment before reduced-intensity conditioning transplantation associates with a decreased incidence of extensive chronic GVHD Biology of Blood and Marrow Transplantation 2009 15 6 671 678
64. Aurer I., Radman I., Nemet D., Gemcitabine in the treatment of relapsed and refractory Hodgkin's disease Onkologie 2005 28 11 567 571
65. Bartlett N. L., Niedzwiecki D., Johnson J. L., Friedberg J. W., Johnson K. B., van Besien K., Zelenetz A. D., Cheson B. D., Canellos G. P., Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804 Annals of Oncology 2007 18 6 1071 1079
66. Cole P. D., Schwartz C. L., Drachtman R. A., De Alarcon P. A., Chen L., Trippett T. M., Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a children's oncology group report Journal of Clinical Oncology 2009 27 9 1456 1461
67. Devizzi L., Santoro L. A., Bonfante L. V., Viviani L. S., Balzarini L. L., Valagussa P., Bonadonna G., Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin's disease Annals of Oncology 1994 5 9 817 820
68. Little R., Wittes R. E., Longo D. L., Wilson W. H., Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant Journal of Clinical Oncology 1998 16 2 584 588
69. Spencer A., Reed K., Arthur C., Pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim Internal Medicine Journal 2007 37 11 760 766
70. Venkatesh H., Di Bella N., Flynn T. P., Vellek M. J., Boehm K. A., Asmar L., Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma Clinical Lymphoma 2004 5 2 110 115
71. Braiteh F., Ng C., Kurzrock R., Refractory Hodgkin lymphoma responds to pentostatin (2′-deoxycoformycin) Leukemia and Lymphoma 2006 47 2 373 375
72. Leonard J. P., Younes A., Rosenblatt J. D., Targeting CD30 as therapy for Hodgkin's disease. Phase II results with the monoclonal antibody SGN-30 Journal of Clinical Oncology 2005 23 16S
73. O'Mahony D., Janik J. E., Carrasquillo J. A., Yttrium-90 radiolabeled humanized monoclonal antibody to CD25 in refractory and relapsed Hodgkin's lymphoma 2008 112. (ASH Annual Meeting Abstracts)
74. Schnell R., Dietlein M., Staak J. O., Borchmann P., Schomaecker K., Fischer T., Eschner W., Hansen H., Morschhauser F., Schicha H., Diehl V., Raubitschek A., Engert A., Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody Journal of Clinical Oncology 2005 23 21 4669 4678
75. Younes A., Wong F., Experience with 90Y-ibritumomab tiuxetan for relapsed classical Hodgkin lymphoma Annals of Oncology 2009 20 6 1147 1148
76. Younes A., Romaguera J., Hagemeister F., McLaughlin P., Rodriguez M. A., Fiumara P., Goy A., Jeha S., Manning J. T. Jr., Jones D., Abruzzo L. V., Medeiros L. J., A pilot study of rituximab in patients with recurrent, classic Hodgkin disease Cancer 2003 98 2 310 314
77. Bociek R. G., Kuruvilla J., Proet B., Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin Lymphoma (HL) Journal of Clinical Oncology 2008 26 15S, supplement
78. O'Connor O. A., Heaney M. L., Schwartz L., Richardson S., Willim R., MacGregor-Cortelli B., Curly T., Moskowitz C., Portlock C., Horwitz S., Zelenetz A. D., Frankel S., Richon V., Marks P., Kelly W. K., Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies Journal of Clinical Oncology 2006 24 1 166 173
79. Bll B., Borchmann P., Topp M. S., Hnel M., Reiners K. S., Engert A., Naumann R., Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma British Journal of Haematology 2010 148 3 480 482
80. Fehninger T. A., Larson S., Trinkaus K., A phase II multicenter study of lenalidomide in patients with relapsed or refractory classical Hodgkin Lymphoma (cHL): preliminary results Blood 2008 112. (ASH Annual Meeting Abstracts)
81. Oki Y., Pro B., Fayad L. E., Romaguera J., Samaniego F., Hagemeister F., Neelapu S., McLaughlin P., Goy A., Younes A., Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma Cancer 2008 112 4 831 836
82. Reiners K. S., Gossmann A., Von Strandmann E. P., Bll B., Engert A., Borchmann P., Effects of the anti-VEGF Monoclonal antibody bevacizumab in a preclinical model and in patients with refractory and multiple relapsed hodgkin lymphoma Journal of Immunotherapy 2009 32 5 508 512
83. Seattle Genetics, Inc, A Pivotal Open-Label Trial of SGN-35 for Hodgkin Lymphoma. NCT:00848926, http://www.clinicaltrials.gov/show/NCT00848926